Animal Model

Loss of the Nf1 Tumor Suppressor Gene Decreases Fas Antigen Expression in Myeloid Cells

Kelly Hiatt,†‡ David A. Ingram,‡§ Hannah Huddleston,† Dan F. Spandau,† Reuben Kapur,† and D. Wade Clapp*†‡

From the Departments of Pediatrics,* Microbiology and Immunology,1 Herman B. Wells Center for Pediatric Research,† Molecular Biology and Biochemistry,3 Medicine and Dermatology,3 Indiana University School of Medicine, Indianapolis, Indiana

Genetic loss of surface Fas antigen expression leads to reduced apoptosis of myeloid and lymphoid progenitor cells, and a propensity to develop autoimmune and myeloid leukemia in mouse models. Oncogenic p21ras decreases surface Fas antigen expression and renders fibroblasts resistant to Fas mediated apoptosis. Neurofibromin, which is encoded by NF1, is a GTPase activating protein that negatively regulates p21ras activity.10,11 Individuals with NF1 and genetically engineered mice harboring mutations at the Nf1 locus have a number of myeloid cell abnormalities.3,4,12–23 Specifically, NF1 patients develop neurofibromas,24 which are infiltrated with a high density of degranulating mast cells, and recent genetic studies in mice suggest that NF1+/− mast cells may play a central role in initiating tumorigenesis.25–28 Further, mice transplanted with Nf1 nullizygous fetal liver hematopoietic stem cells uniformly develop a myeloid leukemia that is highly reminiscent of the juvenile myelomonocytic leukemia observed in children with NF1.19,20,23 Currently, the biochemical and cellular mechanisms underlying the expansion of both myeloid tumor microenvironments.1–5 The mechanisms involved in regulating mast cell numbers following these initiating events are not understood, but are likely complex and dependent on local paracrine or autocrine signals, which activate programmed cell death. Several in vitro studies suggest that Fas antigen (Apo-1/CD95) may directly or indirectly regulate the apoptotic program in mast cells.6–8 Further, Fas antigen-deficient mice (lpr/lpr) have significantly increased numbers of myeloid precursors in both the bone marrow and spleen.9 However, the role of Fas antigen signaling in regulating mast cell numbers in vivo in murine models of mast cell hyperplasia has not been investigated.

Mutations in the NF1 tumor suppressor gene cause neurofibromatosis type 1, a pandemic autosomal dominant genetic disorder with an incidence of 1:3500. Neurofibromin, the protein encoded by NF1, functions as a GTPase activating protein (GAP) for p21ras by accelerating the hydrolysis of active p21ras-GTP to inactive p21ras-GDP.10,11 Individuals with NF1 and genetically engineered mice harboring mutations at the NF1 locus have a number of myeloid cell abnormalities.3,4,12–23 Specifically, NF1 patients develop neurofibromas,24 which are infiltrated with a high density of degranulating mast cells, and recent genetic studies in mice suggest that NF1+/− mast cells may play a central role in initiating tumorigenesis.25–28 Further, mice transplanted with Nf1 nullizygous fetal liver hematopoietic stem cells uniformly develop a myeloid leukemia that is highly reminiscent of the juvenile myelomonocytic leukemia observed in children with NF1.19,20,23 Currently, the biochemical and cellular mechanisms underlying the expansion of both myeloid

Mast cells are important mediators of host immune responses and are active cellular participants in allergic inflammation, neurodegenerative disorders, and some cancers.1,2 Local cutaneous mast cell numbers increase during inflammatory processes, tissue repair, and certain
progenitors and mast cells in NF1 patients is poorly understood.

Fas signaling is tightly regulated by several mechanisms including expression of proteins that directly bind Fas or inhibit caspase activity and mitochondrial events.\(^{29,30}\) Recent studies in non-myeloid cells demonstrate that Fas antigen expression is regulated by downstream p21 ras signaling pathways.\(^{31–33}\) Specifically, oncogenic p21 ras signaling through the phosphoinositide-3-kinase (PI-3K) pathway has been reported to down-regulate Fas antigen expression in immortalized fibroblasts, which renders them resistant to Fas ligand-mediated apoptosis.\(^{32}\) In support of these data, bone marrow-derived mast cells (BMMCs) derived from SH2-containing inositol 5-phosphatase (SHIP)-deficient mice, which have increased PI-3K activation, are insensitive to Fas ligand-mediated cell death.\(^{34}\)

The murine c-kit receptor and its ligand, kit-L, are components of a signaling pathway that promote mast cell proliferation and survival.\(^{35}\) We recently demonstrated that Nf1 heterozygous BMMCs have increased p21 ras activity and PI-3K activation both at baseline and in response to stimulation with kit-L.\(^{3,4}\) As loss of neurofibromin leads to deregulated p21 ras signaling and increased activation of the p21 ras-class Ia, PI-3K pathway, we tested whether Nf1-deficient BMMCs would have a reduction in Fas ligand-mediated apoptosis and Fas antigen expression. Here, using genetic intercrosses between Nf1 +/- and class Ia, PI-3K kinase-deficient mice, we provide genetic and biochemical evidence to demonstrate that Nf1-deficient BMMCs have decreased Fas antigen expression and Fas-ligand mediated apoptosis via hyperactivation of the p21 ras-class Ia PI-3K signaling pathway. Further, we demonstrate that mast cells from both Fas antigen-deficient mice (lor/lpr) and Nf1 +/- mice are resistant to apoptosis following kit-L withdrawal in vivo.

Materials and Methods

Animals

Nf1 +/- mice were obtained from Dr. Tyler Jacks at the Massachusetts Institute of Technology (Cambridge, MA) in a C57BL/6J.129 background and back-crossed for 13 generations into the C57BL/6J strain. p85\(\alpha\) +/- mice were obtained in a C57BL/6J.129 background from Dr. Lewis Cantley at Harvard University (Boston, MA) and back-crossed for 10 generations into a C57BL/6J strain. lor/lpr mice were obtained in a C57BL/6J background from the Jackson Laboratory (Bar Harbor, ME). Multiple FO founders were used to generate mast cells from embryonic day 13.5 fetal liver from the four F2 Nf1 and p85\(\alpha\) genotypes as outlined: FO: Nf1 +/-; +/+. F1: Nf1 +/-; p85\(\alpha\) +/-; +/+. F2: Nf1 +/-; p85\(\alpha\) +/-; +/+. The Nf1 and p85\(\alpha\) alleles were genotyped by polymerase chain reaction (PCR) as previously described.\(^{3,4}\) These studies were conducted with a protocol approved by the Indiana University Laboratory Animal Research Center.

Mast Cell Cultures

Bone marrow-derived mast cells (BMMCs) or fetal liver mast cells (FLMCs) from embryonic day 13.5 fetal liver were established exactly as previously described.\(^{3,4,36}\) BMMCs and FLMCs were cultured as previously described with minor modifications, and the homogeneity of BMMCs and FLMCs was determined by Giemsa staining.\(^{3,4,37}\) Aliquots of cells were also stained alcian blue and safranin to confirm that they were mast cells. Furthermore, fluorescence activated cytometric analysis (FACS) (Becton Dickinson, San Jose, CA) revealed similar forward and side light scatter characteristics and the same percentage of c-kit\(^+\) expression in BMMCs and FLMCs for all murine experimental genotypes (data not shown). For assays examining the expression of cellular surface Fas antigen expression or Fas ligand-mediated cell death, 1 x 10\(^6\) BMMCs or FLMCs were cultured in RPMI media containing 1% L-glutamine (BioWhittaker, Walkersville, MD) in the absence of both growth factors and serum for 16 hours. Mast cells were then cultured in RPMI media containing 10% fetal calf serum (Hyclone, Logan UT), 1% L-glutamine, 2% penicillin/streptomycin (1 mmol/L/ml) (BioWhittaker) and 100 ng/ml of recombinant murine kit-L (Peprotech, Rocky Hill, NJ) for 72 hours. Cells were then examined for expression of Fas antigen or assayed for Fas ligand-mediated apoptosis.

Flow Cytometric Analysis for Fas Antigen Expression

Surface Fas antigen expression was evaluated by fluorescence cytometry. Mast cells were stained for 30 minutes at 4°C with 1 \(\mu\)g/ml of FITC-conjugated anti-Fas monoclonal antibody (Jo-2) (Pharmingen, San Diego, CA) or an isotype control. Cells were washed three times with phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin (BSA) (Sigma, St. Louis, MO) and analyzed by FACS.

Assay for FasL-Induced Cell Death

Following 72 hours of kit-L stimulation (100 ng/ml) as described above, Fas ligand-mediated apoptosis of mast cells was induced by the addition of 100 ng/ml of recombinant human Fas ligand (Upstate Biotec, Waltham, MA). Apoptotic cells were identified by examining DNA fragmentation using the TUNEL method (Roche, Boulder, CO) as previously described.\(^{38}\) Following 16 hours of incubation with recombinant human Fas ligand, TUNEL-positive cells were enumerated by fluorescence cytometry.

Generation of Recombinant Retroviral Plasmids

Previously developed recombinant retrovirus constructs were used in these studies.\(^{37}\) The internal sequences of these constructs are under the transcriptional control of the myeloproliferative sarcoma retrovirus promoter. Constructs also contain a puromycin resistance gene, pac, which is under the transcriptional control of the phospho-
glycerate kinase (PGK) promoter. Three viruses were used in these experiments: a virus expressing the full-length NF1 GTPase activating related domain (NF1 GRD) and pac (MSCV-NF1 GRD-pac); a virus expressing a GAP-inactive mutant of the NF1 GRD that harbors a known human mutation in the arginine finger loop (R1276P)39 and pac (MSCV-1276P NF1 GRD-pac); and a virus expressing the selectable marker gene alone (MSCV-pac).37

Retroviral Transduction of BMMCs or FLMCs

The transduction protocol has been previously described and was used here with minor modifications.37 Briefly, embryonic day 13.5 fetal liver cells recovered from genotyped livers or bone marrow mast cells were pre-stimulated for 48 hours in liquid cultures of RPMI containing 20% fetal bovine serum (Hyclone) supplemented with mitomycin C-treated embryonic day 13.5 fetal liver cells recovered from geno-

Detection of p21ras-GTP Levels

BMMCs were deprived of serum and growth factors for 24 hours and stimulated with 10 ng/ml of kit-L for 5 minutes. p21ras activation was subsequently determined using p21ras activation assay kits (Upstate Biotechnol-

Pl-3 Kinase and ERK Inhibition

BMMCs were preincubated with 5 μmol/L of LY294002 (Sigma), 50 μmol/L of 2D98059 (Cell Signaling, Beverly, MA), or DMSO vehicle control for 2 hours. Following pre-incubation, 100 ng/ml of kit-L was added to cultures for up to 72 hours as described above. Following treat-

In Vivo Cell Survival Assay

Under light avertin anesthesia, micro-osmotic pumps (Al-

Results

Loss of NF1 Results in Resistance to Fas Ligand-Mediated Apoptosis and a Reduction in Surface Fas Antigen Expression

Loss of NF1 increases p21ras activity in NF1 +/− bone marrow cells.4,19,20 To examine whether loss of NF1 renders mast cells resistant to Fas ligand-mediated apoptosis, WT, NF1 +/+ and NF1 −/− BMMCs were cultured in kit-L (100 ng/ml) for 72 hours and then stimulated with recombinant Fas ligand (100 ng/ml) or vehicle control for 16 hours. Following culture, the percentage of cells undergoing apoptosis was deter-

Immunofluorescence

Skin sections were deparaffinized in xylene for 15 min-

Loss of NF1/3 and Fas Expression

Loss of NF1-deficient mast cells were quantitated in a blinded fashion by counting 2 mm² sections in proximity to the India ink stain. Mast cells undergoing apoptosis were detected using a DermaTACS in situ apoptosis detection kit (Trevi-

Histology and with Giemsa to identify mast cells. Cutane-

ous mast cells were quantitated in a blinded fashion by counting 2 mm² sections in proximity to the India ink stain. Mast cells undergoing apoptosis were detected using a DermaTACS in situ apoptosis detection kit (Trevi-

GTPase activating related domain (NF1 GRD) and pac (MSCV-NF1 GRD-pac); a virus expressing a GAP-inactive mutant of the NF1 GRD that harbors a known human mutation in the arginine finger loop (R1276P)39 and pac (MSCV-1276P NF1 GRD-pac); and a virus expressing the selectable marker gene alone (MSCV-pac).37

The transduction protocol has been previously described and was used here with minor modifications.37 Briefly, embryonic day 13.5 fetal liver cells recovered from genotyped livers or bone marrow mast cells were pre-stimulated for 48 hours in liquid cultures of RPMI containing 20% fetal bovine serum (Hyclone) supplemented with mitomycin C-treated embryonic day 13.5 fetal liver cells recovered from geno-

Detection of p21ras-GTP Levels

BMMCs were deprived of serum and growth factors for 24 hours and stimulated with 10 ng/ml of kit-L for 5 minutes. p21ras activation was subsequently determined using p21ras activation assay kits (Upstate Biotechnol-

Pl-3 Kinase and ERK Inhibition

BMMCs were preincubated with 5 μmol/L of LY294002 (Sigma), 50 μmol/L of PD98059 (Cell Signaling, Beverly, MA), or DMSO vehicle control for 2 hours. Following pre-incubation, 100 ng/ml of kit-L was added to cultures for up to 72 hours as described above. Following treat-

In Vivo Cell Survival Assay

Under light avertin anesthesia, micro-osmotic pumps (Al-

Results

Loss of NF1 Results in Resistance to Fas Ligand-Mediated Apoptosis and a Reduction in Surface Fas Antigen Expression

Loss of NF1 increases p21ras activity in NF1 +/− bone marrow cells.4,19,20 To examine whether loss of NF1 renders mast cells resistant to Fas ligand-mediated apoptosis, WT, NF1 +/+ and NF1 −/− BMMCs were cultured in kit-L (100 ng/ml) for 72 hours and then stimulated with recombinant Fas ligand (100 ng/ml) or vehicle control for 16 hours. Following culture, the percentage of cells undergoing apoptosis was deter-

Immunofluorescence

Skin sections were deparaffinized in xylene for 15 min-

Loss of NF1/3 and Fas Expression

Loss of NF1-deficient mast cells were quantitated in a blinded fashion by counting 2 mm² sections in proximity to the India ink stain. Mast cells undergoing apoptosis were detected using a DermaTACS in situ apoptosis detection kit (Trevi-

Histology and with Giemsa to identify mast cells. Cutane-

ous mast cells were quantitated in a blinded fashion by counting 2 mm² sections in proximity to the India ink stain. Mast cells undergoing apoptosis were detected using a DermaTACS in situ apoptosis detection kit (Trevi-

GTPase activating related domain (NF1 GRD) and pac (MSCV-NF1 GRD-pac); a virus expressing a GAP-inactive mutant of the NF1 GRD that harbors a known human mutation in the arginine finger loop (R1276P)39 and pac (MSCV-1276P NF1 GRD-pac); and a virus expressing the selectable marker gene alone (MSCV-pac).37

The transduction protocol has been previously described and was used here with minor modifications.37 Briefly, embryonic day 13.5 fetal liver cells recovered from genotyped livers or bone marrow mast cells were pre-stimulated for 48 hours in liquid cultures of RPMI containing 20% fetal bovine serum (Hyclone) supplemented with mitomycin C-treated embryonic day 13.5 fetal liver cells recovered from geno-

Detection of p21ras-GTP Levels

BMMCs were deprived of serum and growth factors for 24 hours and stimulated with 10 ng/ml of kit-L for 5 minutes. p21ras activation was subsequently determined using p21ras activation assay kits (Upstate Biotechnol-

Pl-3 Kinase and ERK Inhibition

BMMCs were preincubated with 5 μmol/L of LY294002 (Sigma), 50 μmol/L of PD98059 (Cell Signaling, Beverly, MA), or DMSO vehicle control for 2 hours. Following pre-incubation, 100 ng/ml of kit-L was added to cultures for up to 72 hours as described above. Following treat-

In Vivo Cell Survival Assay

Under light avertin anesthesia, micro-osmotic pumps (Al-

Results

Loss of NF1 Results in Resistance to Fas Ligand-Mediated Apoptosis and a Reduction in Surface Fas Antigen Expression

Loss of NF1 increases p21ras activity in NF1 +/− bone marrow cells.4,19,20 To examine whether loss of NF1 renders mast cells resistant to Fas ligand-mediated apoptosis, WT, NF1 +/+ and NF1 −/− BMMCs were cultured in kit-L (100 ng/ml) for 72 hours and then stimulated with recombinant Fas ligand (100 ng/ml) or vehicle control for 16 hours. Following culture, the percentage of cells undergoing apoptosis was deter-

Immunofluorescence

Skin sections were deparaffinized in xylene for 15 min-

Loss of NF1/3 and Fas Expression

Loss of NF1-deficient mast cells were quantitated in a blinded fashion by counting 2 mm² sections in proximity to the India ink stain. Mast cells undergoing apoptosis were detected using a DermaTACS in situ apoptosis detection kit (Trevi-

Histology and with Giemsa to identify mast cells. Cutane-

ous mast cells were quantitated in a blinded fashion by counting 2 mm² sections in proximity to the India ink stain. Mast cells undergoing apoptosis were detected using a DermaTACS in situ apoptosis detection kit (Trevi-
determined by FACS analysis. Nf1+/+ and Nf1−/− cells expressed diminished levels of Fas antigen compared to WT BMMCs (Figure 1B). However, no differences in surface Fas expression between the experimental genotypes were observed before stimulation with kit-L (data not shown). Thus, loss of neurofibromin imparts resistance to Fas ligand-mediated apoptosis in Nf1-deficient mast cells that is directly linked with reduced Fas antigen expression.

Expression of NF1 GAP Related Domains into Nf1−/− Mast Cells Increases Fas Antigen Expression, and Restores Fas Ligand-Mediated Apoptosis.

Expression of recombinant NF1 GAP related domains (GRDs) in primary Nf1-deficient cells restores the activation of the p21ras-Raf-Mek-ERK effector pathway to WT levels.37 To determine whether reduced surface Fas antigen expression in NF1-deficient cells is a function of increased p21ras activity, WT and Nf1−/− mast cells were transduced with a recombinant retrovirus encoding full length NF1 GRD and a selectable marker gene, pac. Following transduction and puromycin selection, mast cells were cultured in serum-enriched medium containing 100 ng/ml of kit-L for 72 hours, and surface Fas antigen expression was examined using fluorescence cytometry. In contrast to Nf1−/− mast cells expressing pac alone, expression of NF1 GRD in Nf1−/− mast cells increased Fas antigen expression to WT levels (Figure 2A). A similar correction was observed when NF1 GRD was expressed in Nf1+/− mast cells. To test whether increased Fas antigen expression correlated with decreased p21ras activity in Nf1−/− mast cells, we examined p21ras-GTP levels in NF1 GRD transduced cells. Expression of NF1 GRD into Nf1−/− mast cells, but not the control sequences (pac), reduced p21ras activity to WT levels (Figure 2B). However, expression of a known human mutant NF1GRD cDNA (R1276P), which contains a single point mutation that reduces NF1 GAP activity by 8000-fold,39 neither restored Fas antigen expression nor increased Fas-induced apoptosis in Nf1−/− mast cells (data not shown). Thus, increased p21ras activity is directly linked to reduced Fas antigen expression in Nf1-deficient cells.

To test whether expression of NF1 GRD sequences into Nf1−/− cells would increase Fas ligand-mediated apoptosis to WT levels, Nf1−/− BMMCs transduced with either the NF1 GRD or the reporter construct sequences only (pac) and WT cells were cultured in kit-L (100 ng/ml) for 72 hours and then stimulated with recombinant Fas ligand (100 ng/ml) or vehicle control for 16 hours. Following culture, the percentage of cells undergoing apoptosis was determined by examining DNA fragmentation using the TUNEL method. Consistent with a restoration of surface Fas antigen expression, Nf1−/− mast cells transduced with the NF1 GRD were sensitive to Fas ligand-mediated apoptosis (Figure 2C).

Genetic Inactivation of Class Ia- PI-3K Activity in NF1-Deficient Mast Cells Restores Fas Antigen Expression and Sensitizes Cells to Fas Ligand-Mediated Apoptosis

Given the biochemical link between p21ras activity and Fas antigen expression in neurofibromin-deficient cells, we next sought to identify which p21ras effector pathways regulate Fas antigen expression. Based on previous studies in immortalized fibroblasts31 and the fact neurofibromin-deficient mast cells have increased PI-3 kinase and ERK activity in response to kit-L,4 we initially tested whether pharmacological inhibition of the PI-3K or the p21ras-Raf-Mek-ERK pathway would alter Fas antigen expression in WT, Nf1−/−, or Nf1−/− mast cells by using specific inhibitors of PI-3K (LY294002), and MEK (PD98059). BMMCs were pre-incubated with serum-enriched media and either LY294002 (5 μmol/L), PD98059 (50 μmol/L), or vehicle control for two hours, and kit-L...
was then added to all cultures. Following 72 hours of culture, surface Fas antigen expression was analyzed by FACS. As was previously observed, Fas antigen expression was reduced in neurofibromatosis-deficient cells treated with vehicle control compared to WT cells (data not shown). While pretreatment with PD98059 did not restore surface Fas antigen expression in Nf1-deficient mast cells, pretreatment with LY294002 significantly increased Fas antigen expression (data not shown). To more rigorously test whether class IA PI-3 kinase alters surface Fas antigen expression, we intercrossed Nf1+/− mice with mice deficient in the p85α regulatory subunit of class IA PI-3K (p85α−/−). While we were not able to generate Nf1−/−, p85α−/− mast cells secondary to the lethality of these embryos, we did establish Nf1+/−, p85α−/− mast cells along with the appropriate experimental controls from embryonic day 13.5 fetal liver to test our hypothesis. Consistent with our prior observations using similar culture conditions, Nf1+/− BMMCs expressed low levels of Fas antigen. However, Nf1+/−; p85α−/− BMMCs had Fas antigen expression comparable to WT controls (Figure 3A) and were sensitive to Fas ligand-mediated apoptosis (Figure 3B). Thus, these results show that increased Fas antigen expression and resistance to Fas ligand-mediated apoptosis in Nf1+/− mast cells is mediated by increased activation of the p21ras-class IA-PI-3K pathway.

**Figure 2.** A–C: Expression of the NFGGRD in Nf1−/− mast cells increases surface Fas antigen expression and Fas ligand-mediated apoptosis. A: Cell surface Fas antigen expression in Nf1−/− mast cells transduced with a recombinant retrovirus expressing the NFGGRD. Following transduction with a recombinant retrovirus expressing either the NFGGRD or a puromycin-resistant gene (pac) and selection in puromycin, WT and Nf1−/− cells were cultured in serum-enriched media and kit-L for 72 hours and surface Fas antigen expression was measured by FACS. The dark profile depicts Fas antigen expression on Nf1-deficient cells transduced with the control virus and the open overlay represents Fas expression by cells transduced with Nf1GRD sequences. The dashed overlay represents Fas expression by WT cells transduced with a retrovirus expressing pac only. Data are representative of five other independent experiments with similar results. B: p21ras-GTP levels in Nf1−/− mast cells transduced with a recombinant retrovirus encoding either the NFGGRD or pac and WT mast cells transduced with a retrovirus encoding pac only. After transduction and selection in puromycin, mast cells were serum starved in the absence of growth factors for 24 hours and then stimulated with kit-L for 5 minutes. p21ras-GTP levels were quantitated as described in Materials and Methods. Data are representative of five independent experiments with similar results. C: Fas ligand-mediated apoptosis in Nf1−/− mast cells transduced with a recombinant retrovirus encoding the NFGGRD. Following transduction with a recombinant retrovirus encoding either the NFGGRD or a puromycin-resistant gene (pac) and selection in puromycin, WT and Nf1−/− cells were cultured in serum-enriched media and kit-L for 72 hours. Following culture, cells were stimulated with either Fas ligand (black bars) or vehicle (white bars). The percentage of cells undergoing apoptosis was determined by FACS analysis using the TUNEL method. Results represent the mean ± SEM of five independent experiments. *P < 0.05 for comparison of Fas ligand-treated and vehicle-treated mast cell cultures within each experimental genotype by Student's paired t-test.

**Mast Cells from Nf1+/− Mice Are Resistant to Apoptosis following kit Ligand Withdrawal and Do Not Express Fas Antigen after Stimulation with kit-L in Vivo**

Injection of polyethylene glycol conjugated kit-L into the skin of WT mice or continuous infusion of kit-L via a
subcutaneous microsomatic pump results in mast cell accumulation at the site of injection that is associated with local mast cell proliferation.4,40,41 To test whether heterozygous inactivation of Nf1 would alter Fas antigen expression in vivo in response to kit-L, we administered kit-L to WT, Nf1 +/−, and Fas antigen-deficient mice (lpr mice) via microsomatic pumps and examined Fas antigen expression by immunofluorescence. Micro-osmotic pumps were filled with a dose of kit-L to administer 20 μg/kg/day for 7 days and placed into the dorsal back skin. This dose of kit-L induces an approximate fivefold and sevenfold increase in the number of mast cells that accumulate in WT and Nf1 +/− mice, respectively.4 In situ immunofluorescence was performed on skin sections taken from mice of the various genotypes following 7 days of kit-L administration. Skin sections were stained with an FITC-conjugated anti-Fas antigen monoclonal antibody (Jo2) or an isotype control, and immunofluorescence on cutaneous mast cells of WT, Nf1 +/+ , and lpr/lpr mice was assessed. Figure 4 demonstrates that mast cells present in skin samples from WT mice express Fas antigen. However, Fas expression could not be detected in either Nf1 +/+ or lpr/lpr cutaneous mast cells (Figure 4). Mast cells in adjacent skin samples did not stain positive when immunofluorescence was performed with an isotype antibody control (data not shown). Thus, these studies verify that the biochemical mechanisms identified in vitro for decreased Fas antigen expression in neurofibromin-deficient mast cells are valid in an experimental model of mast cell stimulation with kit-L in vivo.

Finally, to genetically test the role of Fas antigen expression in regulating mast cells numbers following kit-L withdrawal in vivo, we administered kit-L to WT, Nf1 +/− , and Fas antigen-deficient mice (lpr mice) via micro-osmotic pumps and examined cutaneous mast cell numbers following pump depletion. Withdrawal of kit-L after continuous administration to WT mice has previously been shown to rapidly reduce mast cell numbers by inducing mast cells apoptosis.40 Micro-osmotic pumps were filled with a dose of kit-L to administer 20 μg/kg/day for 7 days and placed into the dorsal back skin. Pumps were removed 5 days following pump depletion and skin biopsies were taken from the site of pump insertion and stained with Giemsa to identify mast cells. Administration of kit-L induced a profound increase in mast cell numbers following kit-L withdrawal.4,12,23 Children with NF1 harboring mutations at the Nf1 locus have a number of myeloid cell abnormalities.3,4,12–23 Individuals with NF1 and genetically engineered mice (lpr mice) via micro-osmotic pumps and examined mast cell numbers following kit-L withdrawal.4 Micro-osmotic pumps were filled with a dose of kit-L to administer 20 μg/kg/day for 7 days and placed into the dorsal back skin. Pumps were removed 5 days following pump depletion and skin biopsies were taken from the site of pump insertion and stained with Giemsa to identify mast cells. Administration of kit-L induced a profound increase in mast cell numbers following kit-L withdrawal.4,12,23 Children with NF1 harboring mutations at the Nf1 locus have a number of myeloid cell abnormalities.3,4,12–23 Individuals with NF1 and genetically engineered mice (lpr mice) via micro-osmotic pumps and examined mast cell numbers following kit-L withdrawal.4 Micro-osmotic pumps were filled with a dose of kit-L to administer 20 μg/kg/day for 7 days and placed into the dorsal back skin. Pumps were removed 5 days following pump depletion and skin biopsies were taken from the site of pump insertion and stained with Giemsa to identify mast cells. Administration of kit-L induced a profound increase in mast cell numbers following kit-L withdrawal.4,12,23 Children with NF1 harboring mutations at the Nf1 locus have a number of myeloid cell abnormalities.3,4,12–23 Individuals with NF1 and genetically engineered mice (lpr mice) via micro-osmotic pumps and examined mast cell numbers following kit-L withdrawal.4 Micro-osmotic pumps were filled with a dose of kit-L to administer 20 μg/kg/day for 7 days and placed into the dorsal back skin. Pumps were removed 5 days following pump depletion and skin biopsies were taken from the site of pump insertion and stained with Giemsa to identify mast cells. Administration of kit-L induced a profound increase in mast cell numbers following kit-L withdrawal.

**Discussion**

Individuals with NF1 and genetically engineered mice harboring mutations at the Nf1 locus have a number of myeloid cell abnormalities.3,4,12–23 Children with NF1 have a 500-fold increased incidence of developing myeloid leukemia associated with a loss of the normal NF1 allele.13,14,18 Though Nf1 −/− mice die in utero from complex cardiovascular abnormalities, adoptive transfer
of Nf1−/− fetal liver stem cells into WT recipients results in the development of a myeloid leukemia that is highly reminiscent of the human disease. The development of neurofibromas, which are complex tumors composed of multiple cell types, is a hallmark of neurofibromatosis type 1. Mast cells infiltrate plexiform and cutaneous neurofibromas in humans as well as murine models of cutaneous tumors where they secrete proteins that can remodel the extracellular matrix and initiate angiogenesis. Consistent with these observations in NF1 patients, we have recently shown that Nf1−/− mast cells have increased proliferation and migration, in response to kit-L and that Nf1−/− mice have increased numbers of cutaneous and peritoneal mast cells. Thus, identification of the biochemical mechanisms responsible for the expansion of Nf1-deficient myeloid cells is critical for understanding disease pathogenesis and the rational design of experimental therapeutics.

Neurofibromin, the protein encoded by NF1, functions as a GAP for p21ras by accelerating the hydrolysis of active p21ras-GTP to inactive p21ras-GDP. We and others have shown that neurofibromin-deficient myeloid progenitors and mast cells have increased p21ras activity in response to multiple hematopoietic cell growth factors, which is directly linked to increased proliferation and migration, in response to kit-L and that Nf1−/− mice have increased numbers of cutaneous and peritoneal mast cells. Thus, identification of the biochemical mechanisms responsible for the expansion of Nf1-deficient myeloid cells is critical for understanding disease pathogenesis and the rational design of experimental therapeutics.

Neurofibromin, the protein encoded by NF1, functions as a GAP for p21ras by accelerating the hydrolysis of active p21ras-GTP to inactive p21ras-GDP. We and others have shown that neurofibromin-deficient myeloid progenitors and mast cells have increased p21ras activity in response to multiple hematopoietic cell growth factors, which is directly linked to increased proliferation.

One of the most potent activators of programmed cell apoptosis in both hematopoietic and non-hematopoietic cell lineages is the death receptor, Fas antigen. Interestingly, recent studies have shown that oncogenic
p21ras inhibits the expression of Fas antigen and renders p21ras-transformed cells resistant to Fas-mediated apoptosis.31,32 The role of Fas signaling in regulating hematopoietic cell numbers has been described in both myeloid and lymphoid cell lineages.9,44 lpr/lpr mice have increased numbers of both myeloid and lymphoid progenitors assayed in bone marrow and spleen compared to wild-type controls.9 Moreover, Fas gene mutations have been implicated in development and progression of myelomas, lymphoid leukemias, and lymphomas.45–47 Given that p21ras activation has been linked to Fas antigen expression and that Fas signaling is important for regulating myeloid cell numbers in vivo, we designed studies to test whether Fas antigen expression was altered in neurofibromin-deficient mast cells.

Using genetic intercrosses between Nf1 +/- and class1a/p13-kinase-deficient mice, we provide several lines of evidence to demonstrate that Nf1-deficient mast cells have decreased Fas antigen expression and Fas-ligand-mediated apoptosis via hyperactivation of the p21ras-class1a/P13-K pathway. These results are consistent with studies in SHIP +/- mast cells, which also have increased PI-3K-Akt activity and are insensitive to Fas-mediated apoptosis.34 Expression of the Nf1 GRD in neurofibromin-deficient mast cells restores p21ras activity to wild-type levels, increases Fas antigen expression and restores sensitivity to Fas ligand. Similar results were observed when pharmacological or genetic inhibition of PI-3K was tested in neurofibromin-deficient mast cells. Importantly, we have also identified a role for Fas ligand-mediated cell death in resolving mast cell numbers in vivo. The resolution kinetics of mast cells following kit-L-induced accumulation are similar in Nf1 +/- mice and lpr/lpr mice and cutaneous mast cells sampled from Nf1 +/- mice do not express detectable levels of Fas antigen in vivo. Finally, while the primary focus of these studies was to determine whether Fas antigen expression was altered in neurofibromin-deficient mast cells, we have initiated studies to test whether Fas antigen expression is decreased in myeloid progenitors harvested from mice transplanted with Nf1 +/- fetal liver hematopoietic stem cells. In preliminary studies, we have observed that Fas antigen expression is decreased in phenotypically defined populations of hematopoietic cells (Sca1+ lin-)31 that are highly enriched for primitive and mature populations of myeloid hematopoietic progenitors (data not shown). Taken together, these results argue that reduced Fas antigen expression contributes at least in part to increased numbers of cutaneous mast cells in Nf1 +/- mice and demonstrate that alterations in p21ras activity can alter Fas antigen expression in primary, non-transformed myeloid cells.

The development of myeloid leukemias and the contribution of mast cells to neurofibroma formation in NF1 patients likely involves increased proliferation and resistance to apoptosis of neurofibromin-deficient cells. Targeting the biochemical pathways responsible for both of these cellular phenotypes is an attractive strategy for treating NF1 patients. Recently, inhibition of oncogenic p21ras by farnesyltransferase inhibitors has been shown to up-regulate Fas antigen expression under both basal growth conditions and in the presence of growth factors.31 Currently, several different farnesyltransferase inhibitors have entered clinical testing in a number of disease states where p21ras is hyperactivated, including NF1 patients with myeloid leukemia. In evaluating the clinical efficacy of these trials and in dissecting the pathogenic mechanisms for the accumulation of mast cells in neurofibromas, it will be important to test whether Fas antigen expression is altered in primary cells harvested from patient specimens. Given that increased PI3-kinase activation is responsible for the reduction in Fas antigen expression in neurofibromin-deficient cells, pharmacological inhibition of PI3-K may also decrease mast cell numbers within neurofibromas or potentially be useful in treating myeloid leukemias in NF1 patients. Finally, since NF1 patients have a wide variety of clinical manifestations including bone abnormalities, learning disorders, vascular abnormalities, and brain tumors, it will be interesting to test whether Fas signaling is altered in other neurofibromin-deficient cell lineages.

Acknowledgments

We thank Marsha Hippensteel for generous supply of p85+/− mice.

References

7. Wagelie-Steffen AL, Hartmann K, Viagofitis H, Metcalfe DD: Fas ligand (FasL, CD95L, APO-1L) expression in murine mast cells. Immunology 1998, 94:569–574